BPMC:NSD-Blueprint Medicines Corp (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 70.98

Change

+2.81 (+4.12)%

Market Cap

USD 4.24B

Volume

0.51M

Avg Analyst Target

USD 83.68 (+17.90%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


BPMC Stock Forecast & Price:
Based on the Blueprint Medicines Corp stock forecasts from 13 analysts, the average analyst target price for Blueprint Medicines Corp is USD 83.68 over the next 12 months. Blueprint Medicines Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Blueprint Medicines Corp is Bearish, which is based on 2 positive signals and 5 negative signals. At the last closing, Blueprint Medicines Corp’s stock price was USD 70.98. Blueprint Medicines Corp’s stock price has changed by +18.89% over the past week, +25.45% over the past month and -24.87% over the last year.

About Blueprint Medicines Corp (BPMC:NSD)

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal st ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-08-10 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Inc

-3.06 (-1.02%)

USD75.25B 29.60 15.72
MRNA Moderna Inc

+3.13 (+1.83%)

USD71.57B 5.79 4.08
REGN Regeneron Pharmaceuticals Inc

+19.34 (+3.11%)

USD67.87B 12.49 9.34
BNTX BioNTech SE

+3.71 (+2.36%)

USD40.37B 3.26 2.01
ALXN Alexion Pharmaceuticals Inc

N/A

USD40.34B 59.23 42.56
SGEN Seagen Inc

+0.05 (+0.03%)

USD32.39B 55.02 -46.79
RPRX Royalty Pharma Plc

+0.25 (+0.57%)

USD29.52B 42.40 20.35
ALNY Alnylam Pharmaceuticals Inc

+8.63 (+3.86%)

USD27.16B N/A -34.32
GMAB Genmab AS

+0.56 (+1.59%)

USD22.96B 73.23 6.37
ARGX argenx NV ADR

+0.21 (+0.06%)

USD20.61B N/A -20.22

ETFs Containing BPMC

Symbol Name Weight Mer Price(Change) Market Cap
BBP Virtus LifeSci Biotech Pr.. 0.00 % 0.79 %

+0.84 (+1.71%)

USD0.01B
IDNA iShares Genomics Immunolo.. 0.00 % 0.47 %

+1.53 (+4.69%)

USD0.22B

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -33.73% 52% F 33% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -33.73% 52% F 33% F
Trailing 12 Months  
Capital Gain -25.46% 74% C 45% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -25.46% 73% C 44% F
Trailing 5 Years  
Capital Gain 53.94% 76% C 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 53.94% 75% C 67% D+
Average Annual (5 Year Horizon)  
Capital Gain 5.94% 59% F 62% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.94% 58% F 58% F
Risk Return Profile  
Volatility (Standard Deviation) 31.68% 86% B 52% F
Risk Adjusted Return 18.75% 65% D 53% F
Market Capitalization 4.24B 94% A 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 19.36 32% F 44% F
Price/Book Ratio 4.04 28% F 24% F
Price / Cash Flow Ratio -14.20 85% B 80% B-
EV/EBITDA -4.47 78% C+ 77% C+
Management Effectiveness  
Return on Equity -67.58% 44% F 19% F
Return on Invested Capital -52.85% 51% F 19% F
Return on Assets -31.54% 38% F 12% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 6.45 27% F 20% F
Short Percent 8.77% 26% F 20% F
Beta 0.94 66% D 60% D-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector